Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07153471 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
A Phase 3 study of Osteoarthritis, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 20
- Study locations
NCT07153471: Recruiting Phase 3 study of Osteoarthritis, sponsored by Eli Lilly and Company.
NCT07153471 is a Phase 3 study of Osteoarthritis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 800 participants, roughly in line with the 812-participant average among 135 other Osteoarthritis trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07153471, a Phase 3 study of Osteoarthritis, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Orforglipron
Study Locations (20)
Arizona
- Arizona Research Center - Phoenix
- AMR Clinical - Tempe
California
- Care Access - Huntington Beach - Huntington Beach
- Care Access - Thousand Oaks - Thousand Oaks
Georgia
- Care Access - Decatur - Decatur
- North Georgia Clinical Research - Woodstock
Missouri
- StudyMetrix Research - City of Saint Peters
- AMR Clinical - Kansas City
Texas
- Mercy Family Clinic - Dallas
- Juno Research - Houston
Colorado
- Legacy Clinical Trials - Colorado Springs
Connecticut
- Chase Medical Research, LLC - Waterbury
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
What NCT07153471 shows while recruiting
NCT07153471 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 812-participant average among 135 other Osteoarthritis trials with a reported enrollment target.
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07153471 names 20 study sites across 15 states, led by Arizona, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07153471 about?
NCT07153471 is a clinical study titled "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee". The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
What is the current status of trial NCT07153471?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2025-09-15. Estimated completion is 2028-05.
What conditions does trial NCT07153471 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT07153471?
The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).
Who is sponsoring clinical trial NCT07153471?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07153471 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07153471's enrollment target sits among peer trials
800 18th of 135 higher than 118 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Beat Pain Better Trial
RECRUITING · Phase 3
-
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RECRUITING · Phase 3
-
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
COMPLETED · Phase 3
-
Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
COMPLETED · Phase 3
-
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
COMPLETED · Phase 3
-
Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI